2015 -- H 5602

========

LC001431

========

     STATE OF RHODE ISLAND

IN GENERAL ASSEMBLY

JANUARY SESSION, A.D. 2015

____________

A N   A C T

RELATING TO INSURANCE - PRESCRIPTION DRUG BENEFITS

     

     Introduced By: Representatives Kennedy, Azzinaro, Keable, Winfield, and Shekarchi

     Date Introduced: February 25, 2015

     Referred To: House Corporations

     It is enacted by the General Assembly as follows:

1

     SECTION 1. Chapter 27-18 of the General Laws entitled "Accident and Sickness

2

Insurance Policies" is hereby amended by adding thereto the following section:

3

     27-18-33.2. Pharmacy benefit manager requirements with respect to multi-source

4

generic pricing updates to pharmacies. – (a) Definitions. As used herein:

5

     (1) "Maximum allowable cost" means the maximum amount that a pharmacy benefits

6

manager will pay toward the cost of a drug;

7

     (2) "Nationally available" means that all pharmacies in this state can purchase the drug,

8

without limitation, from regional or national wholesalers and that the product is not obsolete or

9

temporarily unavailable;

10

     (3) "Therapeutically equivalent" means the equivalent determined by the United States

11

Food and Drug Administration.

12

     (b) "Pharmacy benefit manager" (PBM) means and refers to all requirements with respect

13

to multi-source generic pricing updates to pharmacies:

14

     (1) Upon each contract execution or renewal, a PBM shall, with respect to contracts

15

between PBM and a pharmacy or, alternatively, a PBM and a pharmacy's contracting

16

representative or agent such as a pharmacy services administrative organization (PSAO):

17

     (i) Include in such contracts, the basis of the methodology and sources utilized to

18

determine multi-source generic drug pricing (i.e., maximum allowable cost (MAC)) or any

19

successive benchmark pricing formula) of the PBM, update such pricing information on such at

 

1

least every seven (7) calendar days, and establish a reasonable process for the prompt notification

2

of such pricing updates to network pharmacies; and

3

     (ii) Maintain a procedure to eliminate products from the list of drugs subject to such

4

pricing or modify MAC rates within three (3) days when such drugs do not meet the standards

5

and requirements of this act as set forth in order to remain consistent with pricing changes in the

6

marketplace.

7

     (c) PBM requirements for inclusion of products on a list of drugs subject to multi-source

8

generic pricing:

9

     (1) In order to place a particular prescription drug on a multi-source generic list, the PBM

10

must, at a minimum, ensure that:

11

     (i) The drug have at least three (3) or more nationally available, therapeutically

12

equivalent, multiple source generic drugs;

13

     (ii) The products must be listed as therapeutically and pharmaceutically equivalent rated

14

by the Food and Drug Administration; and

15

     (iii) The product must be available for purchase without limitations by all pharmacies in

16

the state from national or regional wholesalers, and not obsolete or temporarily unavailable.

17

     (d) Standards for pharmacy appeals:

18

     (1) All contracts between a PBM, a contracted pharmacy or, alternatively, a PBM and a

19

pharmacy's contracting representative or agent such as a pharmacy services administrative

20

organization (PSAO) shall include a process to appeal, investigate, and resolve disputes regarding

21

multi-source generic drug pricing. The process shall include the following provisions:

22

     (i) The right to appeal shall be limited to sixty (60) days following the initial claim;

23

     (ii) The appeal shall be investigated and resolved within seven (7) days;

24

     (iii) A telephone number at which a network pharmacy may contact the PBM and speak

25

with an individual who is responsible for processing appeals;

26

     (iv) If the appeal is denied, the PBM shall provide the reason for the denial and identify

27

the national drug code or UDI of a drug product that may be purchased by contracted pharmacies

28

at a price at or below the maximum allowable cost (or benchmark price as determined by the

29

PBM).

30

     (2) If an appeal is upheld, the PBM shall make an adjustment retroactive to the date of

31

initial claim adjudication. The PBM shall make the adjustment effective for all similarly situated

32

pharmacies in this state that are within the network. Any adjustment must be made to all

33

pharmacies within five (5) business days.

34

     (e) The department of business regulation shall exercise oversight and enforcement of

 

LC001431 - Page 2 of 10

1

this section.

2

     SECTION 2. Chapter 27-19 of the General Laws entitled "Nonprofit Hospital Service

3

Corporations" is hereby amended by adding thereto the following section:

4

     27-19-26.1. PBM requirements with respect to multi-source generic pricing updates

5

to pharmacies. -- (a) Definitions. As used herein:

6

     (1) "Maximum allowable cost" means the maximum amount that a pharmacy benefits

7

manager will pay toward the cost of a drug;

8

     (2) "Nationally available" means that all pharmacies in this state can purchase the drug,

9

without limitation, from regional or national wholesalers and that the product is not obsolete or

10

temporarily unavailable;

11

     (3) "Therapeutically equivalent" means the equivalent determined by the United States

12

Food and Drug Administration.

13

     (b) "Pharmacy benefit manager" (PBM) means and refers to all requirements with respect

14

to multi-source generic pricing updates to pharmacies.

15

     (1) Upon each contract execution or renewal, a PBM shall, with respect to contracts

16

between PBM and a pharmacy or, alternatively, a PBM and a pharmacy's contracting

17

representative or agent such as a pharmacy services administrative organization (PSAO):

18

     (i) Include in such contracts, the basis of the methodology and sources utilized to

19

determine multi-source generic drug pricing (i.e., maximum allowable cost (MAC)) or any

20

successive benchmark pricing formula) of the PBM, update such pricing information on such at

21

least every seven (7) calendar days, and establish a reasonable process for the prompt notification

22

of such pricing updates to network pharmacies; and

23

     (ii) Maintain a procedure to eliminate products from the list of drugs subject to such

24

pricing or modify MAC rates within three (3) days when such drugs do not meet the standards

25

and requirements of this act as set forth in order to remain consistent with pricing changes in the

26

marketplace.

27

     (c) PBM requirements for inclusion of products on a list of drugs subject to multi-source

28

generic pricing:

29

     (1) In order to place a particular prescription drug on a multi-source generic list, the PBM

30

must, at a minimum, ensure that:

31

     (i) The drug have at least three (3) or more nationally available, therapeutically

32

equivalent, multiple source generic drugs;

33

     (ii) The products must be listed as therapeutically and pharmaceutically equivalent rated

34

by the Food and Drug Administration; and

 

LC001431 - Page 3 of 10

1

     (iii) The product must be available for purchase without limitations by all pharmacies in

2

the state from national or regional wholesalers, and not obsolete or temporarily unavailable.

3

     (d) Standards for pharmacy appeals:

4

     (1) All contracts between a PBM, a contracted pharmacy or, alternatively, a PBM and a

5

pharmacy's contracting representative or agent such as a pharmacy services administrative

6

organization (PSAO) shall include a process to appeal, investigate, and resolve disputes regarding

7

multi-source generic drug pricing. The process shall include the following provisions:

8

     (i) The right to appeal shall be limited to sixty (60) days following the initial claim;

9

     (ii) The appeal shall be investigated and resolved within seven (7) days;

10

     (iii) A telephone number at which a network pharmacy may contact the PBM and speak

11

with an individual who is responsible for processing appeals;

12

     (iv) If the appeal is denied, the PBM shall provide the reason for the denial and identify

13

the national drug code or UDI of a drug product that may be purchased by contracted pharmacies

14

at a price at or below the maximum allowable cost (or benchmark price as determined by the

15

PBM).

16

     (2) If an appeal is upheld, the PBM shall make an adjustment retroactive to the date of

17

initial claim adjudication. The PBM shall make the adjustment effective for all similarly situated

18

pharmacies in this state that are within the network. Any adjustment must be made to all

19

pharmacies within five (5) business days.

20

     (e) The department of business regulation shall exercise oversight and enforcement of

21

this section.

22

     SECTION 3. Chapter 27-20 of the General Laws entitled "Nonprofit Medical Service

23

Corporations" is hereby amended by adding thereto the following section:

24

     27-20-23.1. Pharmacy benefit manager requirements with respect to multi-source

25

generic pricing updates to pharmacies. -- (a) Definitions. As used herein:

26

     (1) "Maximum allowable cost" means the maximum amount that a pharmacy benefits

27

manager will pay toward the cost of a drug;

28

     (2) "Nationally available" means that all pharmacies in this state can purchase the drug,

29

without limitation, from regional or national wholesalers and that the product is not obsolete or

30

temporarily unavailable;

31

     (3) "Therapeutically equivalent" means the equivalent determined by the United States

32

Food and Drug Administration.

33

     (b) "Pharmacy benefit manager" (PBM) means and refers to all requirements with respect

34

to multi-source generic pricing updates to pharmacies.

 

LC001431 - Page 4 of 10

1

     (1) Upon each contract execution or renewal, a PBM shall, with respect to contracts

2

between PBM and a pharmacy or, alternatively, a PBM and a pharmacy's contracting

3

representative or agent such as a pharmacy services administrative organization (PSAO):

4

     (i) Include in such contracts, the basis of the methodology and sources utilized to

5

determine multi-source generic drug pricing (i.e., maximum allowable cost (MAC)) or any

6

successive benchmark pricing formula) of the PBM, update such pricing information on such at

7

least every seven (7) calendar days, and establish a reasonable process for the prompt notification

8

of such pricing updates to network pharmacies; and

9

     (ii) Maintain a procedure to eliminate products from the list of drugs subject to such

10

pricing or modify MAC rates within three (3) days when such drugs do not meet the standards

11

and requirements of this act as set forth in order to remain consistent with pricing changes in the

12

marketplace.

13

     (c) PBM requirements for inclusion of products on a list of drugs subject to multi-source

14

generic pricing:

15

     (1) In order to place a particular prescription drug on a multi-source generic list, the PBM

16

must, at a minimum, ensure that:

17

     (i) The drug have at least three (3) or more nationally available, therapeutically

18

equivalent, multiple source generic drugs;

19

     (ii) The products must be listed as therapeutically and pharmaceutically equivalent rated

20

by the Food and Drug Administration; and

21

     (iii) The product must be available for purchase without limitations by all pharmacies in

22

the state from national or regional wholesalers, and not obsolete or temporarily unavailable.

23

     (d) Standards for pharmacy appeals:

24

     (1) All contracts between a PBM, a contracted pharmacy or, alternatively, a PBM and a

25

pharmacy's contracting representative or agent such as a pharmacy services administrative

26

organization (PSAO) shall include a process to appeal, investigate, and resolve disputes regarding

27

multi-source generic drug pricing. The process shall include the following provisions:

28

     (i) The right to appeal shall be limited to sixty (60) days following the initial claim;

29

     (ii) The appeal shall be investigated and resolved within seven (7) days;

30

     (iii) A telephone number at which a network pharmacy may contact the PBM and speak

31

with an individual who is responsible for processing appeals;

32

     (iv) If the appeal is denied, the PBM shall provide the reason for the denial and identify

33

the national drug code or UDI of a drug product that may be purchased by contracted pharmacies

34

at a price at or below the maximum allowable cost (or benchmark price as determined by the

 

LC001431 - Page 5 of 10

1

PBM).

2

     (2) If an appeal is upheld, the PBM shall make an adjustment retroactive to the date of

3

initial claim adjudication. The PBM shall make the adjustment effective for all similarly situated

4

pharmacies in this state that are within the network. Any adjustment must be made to all

5

pharmacies within five (5) business days.

6

     (e) The department of business regulation shall exercise oversight and enforcement of

7

this section.

8

     SECTION 4. Chapter 27-20.1 of the General Laws entitled "Nonprofit Dental Service

9

Corporations" is hereby amended by adding thereto the following section:

10

     27-20.1-15.1. Pharmacy benefit manager requirements with respect to multi-source

11

generic pricing updates to pharmacies. -- (a) Definitions. As used herein:

12

     (1) "Maximum allowable cost" means the maximum amount that a pharmacy benefits

13

manager will pay toward the cost of a drug;

14

     (2) "Nationally available" means that all pharmacies in this state can purchase the drug,

15

without limitation, from regional or national wholesalers and that the product is not obsolete or

16

temporarily unavailable;

17

     (3) "Therapeutically equivalent" means the equivalent determined by the United States

18

Food and Drug Administration.

19

     (b) "Pharmacy benefit manager (PBM)" means and refers to all requirements with respect

20

to multi-source generic pricing updates to pharmacies.

21

     (1) Upon each contract execution or renewal, a PBM shall, with respect to contracts

22

between PBM and a pharmacy or, alternatively, a PBM and a pharmacy's contracting

23

representative or agent such as a pharmacy services administrative organization (PSAO):

24

     (i) Include in such contracts, the basis of the methodology and sources utilized to

25

determine multi-source generic drug pricing (i.e., maximum allowable cost (MAC)) or any

26

successive benchmark pricing formula) of the PBM, update such pricing information on such at

27

least every seven (7) calendar days, and establish a reasonable process for the prompt notification

28

of such pricing updates to network pharmacies; and

29

     (ii) Maintain a procedure to eliminate products from the list of drugs subject to such

30

pricing or modify MAC rates within three (3) days when such drugs do not meet the standards

31

and requirements of this act as set forth in order to remain consistent with pricing changes in the

32

marketplace.

33

     (c) PBM requirements for inclusion of products on a list of drugs subject to multi-source

34

generic pricing:

 

LC001431 - Page 6 of 10

1

     (1) In order to place a particular prescription drug on a multi-source generic list, the PBM

2

must, at a minimum, ensure that:

3

     (i) The drug have at least three (3) or more nationally available, therapeutically

4

equivalent, multiple source generic drugs;

5

     (ii) The products must be listed as therapeutically and pharmaceutically equivalent rated

6

by the Food and Drug Administration; and

7

     (iii) The product must be available for purchase without limitations by all pharmacies in

8

the state from national or regional wholesalers, and not obsolete or temporarily unavailable.

9

     (d) Standards for pharmacy appeals:

10

     (1) All contracts between a PBM, a contracted pharmacy or, alternatively, a PBM and a

11

pharmacy's contracting representative or agent such as a pharmacy services administrative

12

organization (PSAO) shall include a process to appeal, investigate, and resolve disputes regarding

13

multi-source generic drug pricing. The process shall include the following provisions:

14

     (i) The right to appeal shall be limited to sixty (60) days following the initial claim;

15

     (ii) The appeal shall be investigated and resolved within seven (7) days;

16

     (iii) A telephone number at which a network pharmacy may contact the PBM and speak

17

with an individual who is responsible for processing appeals;

18

     (iv) If the appeal is denied, the PBM shall provide the reason for the denial and identify

19

the national drug code or UDI of a drug product that may be purchased by contracted pharmacies

20

at a price at or below the maximum allowable cost (or benchmark price as determined by the

21

PBM).

22

     (2) If an appeal is upheld, the PBM shall make an adjustment retroactive to the date of

23

initial claim adjudication. The PBM shall make the adjustment effective for all similarly situated

24

pharmacies in this state that are within the network. Any adjustment must be made to all

25

pharmacies within five (5) business days.

26

     (e) The department of business regulation shall exercise oversight and enforcement of

27

this section.

28

     SECTION 5. Chapter 27-41 of the General Laws entitled "Health Maintenance

29

Organizations" is hereby amended by adding thereto the following section:

30

     27-41-38.1. Pharmacy benefit manager requirements with respect to multi-source

31

generic pricing updates to pharmacies. -- (a) Definitions. As used herein:

32

     (1) "Maximum allowable cost" means the maximum amount that a pharmacy benefits

33

manager will pay toward the cost of a drug;

34

     (2) "Nationally available" means that all pharmacies in this state can purchase the drug,

 

LC001431 - Page 7 of 10

1

without limitation, from regional or national wholesalers and that the product is not obsolete or

2

temporarily unavailable;

3

     (3) "Therapeutically equivalent" means the equivalent determined by the United States

4

Food and Drug Administration.

5

     (b) "Pharmacy benefit manager" (PBM) means and refers to all requirements with respect

6

to multi-source generic pricing updates to pharmacies.

7

     (1) Upon each contract execution or renewal, a PBM shall, with respect to contracts

8

between PBM and a pharmacy or, alternatively, a PBM and a pharmacy's contracting

9

representative or agent such as a pharmacy services administrative organization (PSAO):

10

     (i) Include in such contracts, the basis of the methodology and sources utilized to

11

determine multi-source generic drug pricing (i.e., maximum allowable cost (MAC)) or any

12

successive benchmark pricing formula) of the PBM, update such pricing information on such at

13

least every seven (7) calendar days, and establish a reasonable process for the prompt notification

14

of such pricing updates to network pharmacies; and

15

     (ii) Maintain a procedure to eliminate products from the list of drugs subject to such

16

pricing or modify MAC rates within three (3) days when such drugs do not meet the standards

17

and requirements of this act as set forth in order to remain consistent with pricing changes in the

18

marketplace.

19

     (c) PBM requirements for inclusion of products on a list of drugs subject to multi-source

20

generic pricing:

21

     (1) In order to place a particular prescription drug on a multi-source generic list, the PBM

22

must, at a minimum, ensure that:

23

     (i) The drug have at least three (3) or more nationally available, therapeutically

24

equivalent, multiple source generic drugs;

25

     (ii) The products must be listed as therapeutically and pharmaceutically equivalent rated

26

by the Food and Drug Administration; and

27

     (iii) The product must be available for purchase without limitations by all pharmacies in

28

the state from national or regional wholesalers, and not obsolete or temporarily unavailable.

29

     (d) Standards for pharmacy appeals:

30

     (1) All contracts between a PBM, a contracted pharmacy or, alternatively, a PBM and a

31

pharmacy's contracting representative or agent such as a pharmacy services administrative

32

organization (PSAO) shall include a process to appeal, investigate, and resolve disputes regarding

33

multi-source generic drug pricing. The process shall include the following provisions:

34

     (i) The right to appeal shall be limited to sixty (60) days following the initial claim;

 

LC001431 - Page 8 of 10

1

     (ii) The appeal shall be investigated and resolved within seven (7) days;

2

     (iii) A telephone number at which a network pharmacy may contact the PBM and speak

3

with an individual who is responsible for processing appeals;

4

     (iv) If the appeal is denied, the PBM shall provide the reason for the denial and identify

5

the national drug code or UDI of a drug product that may be purchased by contracted pharmacies

6

at a price at or below the maximum allowable cost (or benchmark price as determined by the

7

PBM).

8

     (2) If an appeal is upheld, the PBM shall make an adjustment retroactive to the date of

9

initial claim adjudication. The PBM shall make the adjustment effective for all similarly situated

10

pharmacies in this state that are within the network. Any adjustment must be made to all

11

pharmacies within five (5) business days.

12

     (e) The department of business regulation shall exercise oversight and enforcement of

13

this section.

14

     SECTION 6. This act shall take effect upon passage.

========

LC001431

========

 

LC001431 - Page 9 of 10

EXPLANATION

BY THE LEGISLATIVE COUNCIL

OF

A N   A C T

RELATING TO INSURANCE - PRESCRIPTION DRUG BENEFITS

***

1

     This act would regulate business relationship between pharmacy services providers/group

2

health insurers/health service organizations with department of business regulation oversight.

3

     This act would take effect upon passage.

========

LC001431

========

 

LC001431 - Page 10 of 10